{"id":111,"date":"2022-07-27T10:00:00","date_gmt":"2022-07-27T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=111"},"modified":"2025-09-01T03:54:25","modified_gmt":"2025-09-01T03:54:25","slug":"china-bd-deal-2022-kelun-biotech-and-msd-enters-a-935-million-usd-license-on-trop2-adc-skb-264","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2022\/111.html","title":{"rendered":"[China BD deal 2022] Kelun-Biotech and MSD enters a 935 million USD license on \u00a0TROP2 ADC SKB-264"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2022-07-26 (July 26, 2022)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: SKB-264 (MK-2870)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd, China)&nbsp; <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): &nbsp;MSD (Merck &amp; Co., Inc. USA)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality:  Antibody drug conjugate (ADC)&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: &nbsp;TROP2<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: Phase 3\u3001Phase 2<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kelun-Biotech has granted MSD global, exclusive rights to develop, manufacture and commercialize an investigational ADC. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kelun-Biotech and MSD will also collaborate on the early clinical development of the investigational ADC.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Deal Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment of&nbsp;$35 million,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Milestone payments up to &nbsp;$901 million,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Total up to $935 million.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Plus tiered royalties on net sales.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kelun-Biotech Announces Oncology Research Collaboration and License Agreement with MSD<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/en.kelun-biotech.com\/newsCenter.aspx?mid=18\">Newsroom &#8211; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2022-07-26 (July 26, 2022) Asset Name: SKB-264 (MK-2870) Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun &hellip; <a title=\"[China BD deal 2022] Kelun-Biotech and MSD enters a 935 million USD license on \u00a0TROP2 ADC SKB-264\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2022\/111.html\"><span class=\"screen-reader-text\">[China BD deal 2022] Kelun-Biotech and MSD enters a 935 million USD license on \u00a0TROP2 ADC SKB-264<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-111","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=111"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/111\/revisions"}],"predecessor-version":[{"id":114,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/111\/revisions\/114"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}